On March 12, 2020 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported that the company will hold its planned investor meetings virtually at the 32nd Annual ROTH Conference following the decision by ROTH to hold the conference online on March 17 (Press release, CohBar, MAR 12, 2020, View Source [SID1234555508]). The company was previously invited to speak on a panel titled "Great Oaks Come from Little Acorns in NASH, CVD and CKD", hosted by the Co-Head of Biotechnology Research, Yasmeen Rahimi, PhD. However, all panel sessions have since been cancelled.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!